Tolerability and efficacy of L-asparaginase therapy in pediatric patients with acute lymphoblastic leukemia

Journal of Pediatric Hematology/Oncology

Volumn 32, Issue 7, 2010, Pages 554-563

  Raetz, Elizabeth A ^a   Salzer, Wanda L ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Acute lymphoblastic leukemia; Hypersensitivity; L asparaginase; Pegaspargase; Toxicity

Indexed keywords

ASPARAGINASE; ANTINEOPLASTIC AGENT; ASPARAGINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; COMA; CONFUSION; DEPRESSION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; ENZYME ACTIVITY; ESCHERICHIA COLI; EVENT FREE SURVIVAL; FATIGUE; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERGLYCEMIA; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION; LETHARGY; LEUKOCYTE COUNT; LIVER DYSFUNCTION; METASTASIS; PANCREATITIS; PECTOBACTERIUM CHRYSANTHEMI; PRIORITY JOURNAL; PROTEIN SYNTHESIS; SOMNOLENCE; VENOUS THROMBOEMBOLISM; CHILD; REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINE; CHILD; HUMANS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 77958159829     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3181e6f003     Document Type: Article

References (104)

1. Jaffe N, Traggis D, Das L, et al. L-asparaginase in the treatment of neoplastic diseases in children. Cancer Res. 1971; 31:942-949.
2. Capizzi RL, Bertino JR, Skeel RT, et al. L-asparaginase: clinical, biochemical, pharmacological, and immunological studies. Ann Intern Med. 1971;74:893-901.
3. Clavell LA, Gelber RD, Cohen HJ, et al. Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. N Engl J Med. 1986;315:657-663.
4. Jones B, Holland JF, Glidewell O, et al. Optimal use of L-asparaginase (NSC-109229) in acute lymphocytic leukemia. Med Pediatr Oncol. 1977;3:387-400.
5. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354:166-178.
6. Pui C-H, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet 2008;371:1030-1043.
7. Tallal L, Tan C, Oettgen H, et al. E. coli L-asparaginase in the treatment of leukemia and solid tumors in 131 children. Cancer. 1970;25:306-320.
8. Ertel IJ, Nesbit ME, Hammond D, et al. Effective dose of L-asparaginase for induction of remission in previously treated children with acute lymphocytic leukemia: a report from Childrens Cancer Study Group. Cancer Res. 1979;39:3893-3896.
9. Appel IM, Kazemier KM, Boos J, et al. Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia: results from a single agent window study. Leukemia. 2008;22:1665-1679.
10. Nesbit ME, Ertel I, Hammond GD. L-Asparaginase as a single agent in acute lymphocytic leukemia: survey of studies form Childrens Cancer Study Group. Cancer Treat Rep. 1981;65(suppl 4):101-107.
11. Sutow WW, Garcia F, Starling KA, et al. L-asparaginase therapy in children with advanced leukemia: The Southwest cancer chemotherapy study group. Cancer. 1971;28:819-824.
12. Ho DHW, Whitecar JP Jr, Luce JK, et al. L-Asparagine Requirement and the effect of L-Asparaginase on the normal and leukemic human bone marrow. Cancer Res. 1970;30:466-472.
13. Broome JD. Studies on the mechanism of tumor inhibition by L-asparaginase. Effects of the enzyme on asparagine levels in the blood, normal tissues, and 6C3HED lymphomas of mice: Differences in asparagine formation and utilization in asparaginase-sensitive and -resistant lymphoma cells. J Exp Med. 1968;127:1055-1072.
14. Aslanian AM, Fletcher BS, Kilberg MS. Asparagine synthetase expression alone is sufficient to induce l-asparaginase resistance in MOLT-4 human leukaemia cells. Biochem J. 2001;357:321-328.
15. Haskell CM, Canellos GP. L-asparaginase resistance in human leukemia-asparagine synthetase. Biochem Pharmacol. 1969;18:2578-2580.
16. Hutson RG, Kitoh T, Moraga Amador DA, et al. Amino acid control of asparagine synthetase: relation to asparaginase resistance in human leukemia cells. Am J Physiol. 1997;272: C1691-C1699.
17. Iwamoto S, Mihara K, Downing J, et al. Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J Clin Invest. 2007;117:1049-1057. (Pubitemid 46556761)
18. Appel IM, den Boer ML, Meijerink JPP, et al. Up-regulation of asparagine synthetase expression is not linked to the clinical response L-asparaginase in pediatric acute lymphoblastic leukemia. Blood. 2006;107:4244-4249.
19. Stams WAG, den Boer M, Holleman A, et al. Asparagine synthetase expression is linked with L-asparaginase resistance in TEL-AML1-negative but not TEL-AML1-positive pediatric acute lymphoblastic leukemia. Blood. 2005;105:4223-4225.
20. Asselin B, Whitin J, Coppola D, et al. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol. 1993;11:1780-1786.
21. Avramis VI, Sencer S, Periclou AP, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Childrens Cancer Group study. Blood. 2002;99:1986-1994.
22. Avramis VI, Panosyan EH. Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future. Clin Pharmacokinetic. 2005;44:367-393.
23. Panetta JC, Gajjar A, Hijiya N, et al. Comparison of native E. coli and PEG asparaginase pharmacokinetics and pharmacodynamics in pediatric acute lymphoblastic leukemia. Clin Pharmacol Ther. 2009;86:651-658.
24. Land VJ, Sutow WW, Fernbach DJ, et al. Toxicity of Lasparginase in children with advanced leukemia. Cancer. 1972;30:339-347.
25. Dinndorf P, Gootenberg J, Cohen M, et al. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). Oncologist. 2007;12:991-998.
26. Albertsen BK, Schrder H, Ingerslev J, et al. Comparison of intramuscular therapy with Erwinia asparaginase and asparaginase Medac: pharmacokinetics, pharmacodynamics, formation of antibodies and influence on the coagulation system. Br J Haematol. 2001;115:983-990.
27. Avramis V, Spence S. Clinical pharmacology of asparaginases in the United States: asparaginase population pharmacokinetic and pharmacodynamic (PK-PD) models (NONMEM) in adult and pediatric ALL patients. J Pediatr Hematol Oncol. 2007;29:239-247.
28. Boos J, Werber G, Ahlke E, et al. Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations. Eur J Cancer. 1996;32:1544-1550. (Pubitemid 26279122)
29. Vieira Pinheiro JP, Ahlke E, Nowak-Gottl U, et al. Pharmacokinetic dose adjustment of Erwinia asparaginase in protocol II of the paediatric ALL/NHL-BFM treatment protocols. Br J Haematol. 1999;104:313-320.
30. Muller HJ, Lning L, Horn A, et al. Pegylated asparaginase (Oncaspar) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols. Br J Haematol. 2000;110:379-384.
31. Asselin BL, Lorenson MY, Whitin JC, et al. Measurement of serum L-asparagine in the presence of L-asparaginase requires the presence of an L-asparaginase inhibitor. Cancer Res. 1991;51:6568-6573.
32. Gentili D, Conter V, Rizzari C, et al. L-Asparagine depletion in plasma and cerebro-spinal fluid of children with acute lymphoblastic leukemia during subsequent exposures to Erwinia L-asparaginase. Ann Oncol. 1996;7:725-730.
33. Avramis V, Avramis E, Hunter W, et al. Immunogenicity of native or pegylated E. coli and Erwinia asparaginases assessed by ELISA and surface plasmon resonance (SPR-biacore) assays of IgG antibodies (Ab) in sera from patients with acute lymphoblastic leukemia (ALL). Anticancer Res. 2009;29: 299-302.
34. Zalewska-Szewczyk B, Gach A, Wyka K, et al. The cross-reactivity of anti-asparaginase antibodies against different L-asparaginase preparations. Clin Exp Med. 2009;9: 113-116.
35. Tiwari PN, Zielinski M, Quinn JJ, et al. Assessment of antiasparaginase (ASNase) antibodies (Ab) and ASNase activity after suspected clinical allergy. ASH Annual Meeting Abstracts. 2006;108:1878.
36. Cairo MS. Adverse reactions of L-asparaginase. Am J Pediatr Hematol Oncol. 1982;4:335-339.
37. Evans WE, Tsiatis A, Rivera G, et al. Anaphylactoid reactions to Escherichia coli and Erwinia asparaginase in children with leukemia and lymphoma. Cancer. 1982;49:1378-1383.
38. Zalewska-Szewczyk B, Andrzejewski W, Mlynarski Lynarski W, et al. The anti-asparagines antibodies correlate with Lasparagines activity and may affect clinical outcome of childhood acute lymphoblastic leukemia. Leukemia Lymphoma. 2007;48:931-936.
39. Muller HJ, Beier R, Lning L, et al. Pharmacokinetics of native Escherichia coli asparaginase (Asparaginase medac) and hypersensitivity reactions in ALL-BFM 95 reinduction treatment. Br J Haematol. 2001;114:794-799.
40. Seibel NL, Steinherz PG, Sather HN, et al. Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Childrens Oncology Group. Blood. 2008;111: 2548-2555.
41. Woo MH, Hak LJ, Storm MC, et al. Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol. 2000;18:1525-1532.
42. Wacker P, Land V, Camitta B, et al. Allergic reactions to E. coli L-asparaginase do not affect outcome in childhood B-precursor acute lymphoblastic leukemia: a Childrens Oncology Group Study. J Pediatr Hematol Oncol. 2007;29: 627-632.
43. Vrooman LM, Supko JG, Neuberg DS, et al. Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2010;54:199-205.
44. Moghrabi A, Levy DE, Asselin B, et al. Results of the Dana- Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood. 2007;109: 896-904.
45. Larson RA, Fretzin MH, Dodge RK, et al. Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia. Leukemia. 1998;12:660-665.
46. Nesbit M, Chard R, Evans A, et al. Evaluation of intramuscular versus intravenous administration of L-asparaginase in childhood leukemia. Am J Pediatr Hematol Oncol. 1979;1:9-13.
47. Douer D, Yampolsky H, Cohen LJ, et al. Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Blood. 2007;109: 2744-2750.
48. Muller H-J, Beier R, da Palma J, et al. PEG-asparaginase (Oncaspar) 2500 U/m(2) BSA in reinduction and relapse treatment in the ALL/NHL-BFM protocols. Cancer Chemother Pharmacol. 2002;49:149-154.
49. Vieira Pinheiro JP, Wenner K, Escherich G, et al. Serum asparaginase activities and asparagine concentrations in the cerebrospinal fluid after a single infusion of 2500 IU/m(2) PEG asparaginase in children with ALL treated according to protocol COALL-06-97. Pediatr Blood Cancer. 2006;46: 18-25.
50. Silverman LB, Stevenson K, Neuberg D, et al. Intravenous PEG asparaginase during remission induction for childhood ALL. ASH Annual Meeting Abstracts. 2006;108:1854.
51. Fu C, Sakamoto K. PEG-asparaginase. Expert Opin Pharmacother. 2007;8:1977-1984.
52. Panosyan EH, Seibel NL, Martin-Aragon S, et al. Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Childrens Cancer Group Study CCG-1961. J Pediatr Hematol Oncol. 2004;26: 217-226.
53. King OY, Wilbur JR, Mumford DM, et al. Therapy with Erwinia L-asparaginase in children with acute leukemia after anaphylaxis to E. coli L-asparaginase. Cancer. 1974;33: 611-614.
54. Billett AL, Sallan SE, Carls A, et al. Allergic reactions to Erwinia asparaginase in children with acute lymphoblastic leukemia who had previous allergic reactions to E Coli. asparaginase. Cancer. 1992;70:201-206.
55. Ohnuma T, Holland JF, Meyer P. Erwinia carotovora asparaginase in patients with prior anaphylaxis to asparaginase from E. coli. Cancer. 1972;30:376-381.
56. Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood. 2001;97:1211-1218.
57. Holcenberg J. Optimal asparaginase therapy. J Pediatr Hematol Oncol. 2004;26:273-274.
58. Woo MH, Hak LJ, Storm MC, et al. Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia. Leukemia. 1998;12:1527-1533.
59. Killander D, Dohlwitz A, Engstedt L, et al. Hypersensitive reactions and antibody formation during L-asparaginase treatment of children and adults with acute leukemia. Cancer. 1976;37:220-228.
60. Oettgen HF, Stephenson PA, Schwartz MK, et al. Toxicity of E. coli L-asparaginase in man. Cancer. 1970;25:253-278.
61. Salzer WL, Devidas M, Shuster JJ, et al. Intensified PEGL- asparaginase and antimetabolite-based therapy for treatment of higher risk precursor-B acute lymphoblastic leukemia: a report from the Childrens Oncology Group. J Pediatr Hematol Oncol. 2007;29:369-375.
62. Abshire TC, Pollock BH, Billett AL, et al. Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study. Blood. 2000;96:1709-1715.
63. Amylon MD, Shuster J, Pullen J, et al. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. Leukemia. 1999;13:335-342.
64. Nachman JB, Sather HN, Sensel MG, et al. Augmented postinduction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med. 1998;338:1663-1671.
65. Barry E, DeAngelo DJ, Neuberg D, et al. Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber cancer institute acute lymphoblastic leukemia consortium protocols. J Clin Oncol. 2007;25:813-819. (Pubitemid 350002881)
66. Sahu S, Saika S, Pai SK, et al. L-asparaginase (Leunase) induced pancreatitis in childhood acute lymphoblastic leukemia. Pediatr Hematol Oncol. 1998;15:533-538.
67. Alvarez OA, Zimmerman G. Pegaspargase-induced pancreatitis. Med Pediatr Oncol. 2000;34:200-205.
68. Weetman RM, Baehner RL. Latent onset of clinical pancreatitis in children receiving L-asparaginase therapy. Cancer. 1974;34:780-785.
69. Wu S-F, Chen A-C, Peng C-T, et al. Octreotide therapy in asparaginase-associated pancreatitis in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2008;51:824-825.
70. Garrington T, Bensard D, Ingram JD, et al. Successful management with octreotide of a child with L-asparaginase induced hemorrhagic pancreatitis. Med Pediatr Oncol. 1998;30:106-109. (Pubitemid 128765925)
71. Knoderer HM, Robarge J, Flockhart DA. Predicting asparaginase-associated pancreatitis. Pediatr Blood Cancer. 2007;49:634-639.
72. Duval M, Suciu S, Ferster A, et al. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Childrens Leukemia Group phase 3 trial. Blood. 2002;99:2734-2739.
73. Kearney S, Dahlberg S, Levy D, et al. Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis. Pediatr Blood Cancer. 2009;53:162-167.
74. Athale U, Siciliano S, Thabane L, et al. Epidemiology and clinical risk factors predisposing to thromboembolism in children with cancer. Pediatr Blood Cancer. 2008;51:792-797.
75. Athale UH, Chan AKC. Thrombosis in children with acute lymphoblastic leukemia: Part I. Epidemiology of thrombosis in children with acute lymphoblastic leukemia. Thromb Res. 2003;111:125-131.
76. Payne JH, Vora AJ. Thrombosis and acute lymphoblastic leukaemia. Br J Haematol. 2007;138:430-445.
77. Nowak-Göttl U, Heinecke A, von Kries R, et al. Thrombotic events revisited in children with acute lymphoblastic leukemia: impact of concomitant escherichia coli asparaginase/ prednisone administration. Thromb Res. 2001;103:165-172.
78. Appel IM, Hop WC, van Kessel-Bakvis C, et al. L-Asparaginase and the effect of age on coagulation and fibrinolysis in childhood acute lymphoblastic leukemia. Thromb Haemost. 2008;100:330-337.
79. Ohnuma T, Holland JF, Freeman A, et al. Biochemical and pharmacological studies with asparaginase in man. Cancer Res. 1970;30:2297-2305.
80. Feinberg WM, Swenson MR. Cerebrovascular complications of L-asparaginase therapy. Neurology. 1988;38:127-133.
81. Kieslich M, Porto L, Lanfermann H, et al. Cerebrovascular complications of L-asparaginase in the therapy of acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2003;25: 484-487.
82. Carpentieri U, Balch MT. Hyperglycemia associated with the therapeutic use of L-asparaginase: possible role of insulin receptors. J Pediatr. 1978;93:775-778.
83. Lavine RL, Brodsky I, Garofano CD, et al. The effect of E. coli L-asparaginase on oral glucose tolerance and insulin release in man. Diabetologia. 1978;15:113-116.
84. Turner GR, Marks JF, Buchanan GR. Relative hyperglucagonemia in L-asparaginase-and prednisone-induced glucose intolerance in management of acute lymphocytic leukemia. Clin Pediatr. 1983;22:363-367.
85. Pui CH, Burghen GA, Bowman WP, et al. Risk factors for hyperglycemia in children with leukemia receiving L-asparaginase and prednisone. J Pediatr. 1981;99:46-50.
86. Roberson JR, Raju S, Shelso J, et al. Diabetic ketoacidosis during therapy for pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer. 2008;50:1207-1212.
87. Pratt CB, Simone JV, Zee P, et al. Comparison of daily versus weekly L-asparaginase for the treatment of childhood acute leukemia. J Pediatr. 1970;77:474-483.
88. Pratt CB, Johnson WW. Duration and severity of fatty metamorphosis of the liver following L-asparaginase therapy. Cancer. 1971;28:361-364.
89. Biggs JC, Chesterman CN, Holliday J. L-asparaginase-clinical experience in leukaemia, lymphoma and carcinoma. Austral N Z J Med. 1971;1:1-7.
90. Sahoo S, Hart J. Histopathological features of L-asparaginase- induced liver disease. Sem Liv Dis. 2003;23:295-299.
91. Bodmer M, Sulz M, Stadlmann S, et al. Fatal liver failure in an adult patient with acute lymphoblastic leukemia following treatment with L-asparaginase. Digestion. 2006;74:28-32.
92. Parsons SK, Skapek SX, Neufeld EJ, et al. Asparaginaseassociated lipid abnormalities in children with acute lymphoblastic leukemia. Blood. 1997;89:1886-1895.
93. Harris MB, Shuster JJ, Pullen J, et al. Treatment of children with early pre-B and pre-B acute lymphocytic leukemia with antimetabolite-based intensification regimens: a Pediatric Oncology Group Study. Leukemia. 2000;14:1570-1576.
94. Pui CH, Relling MV, Behm FG, et al. L-asparaginase may potentiate the leukemogenic effect of the epipodophyllotoxins. Leukemia. 1995;9:1680-1684.
95. Felix CA. Secondary leukemias induced by topoisomerasetargeted drugs. Biochim Biophys Acta. 1998;1400:233-255.
96. Blanco J, Edick M, Hancock M, et al. Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies. Pharmacogenetics. 2002;12:605-611.
97. Broome JD. Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects: I. properties of the L-asparaginase of guinea pig serum in relation to those of the antilymphoma substance. J Exp Med 1963;118: 99-120.
98. Dolowy WC, Henson D, Cornet J, et al. Toxic and antineoplastic effects of l-asparaginase: study of mice with lymphoma and normal monkeys and report on a child with leukemia. Cancer. 1966;19:1813-1819.
99. Ortega JA, Nesbit ME Jr, Donaldson MH, et al. L-Asparaginase, vincristine, and prednisone for induction of first remission in acute lymphocytic leukemia. Cancer Res. 1977;37:535-540.
100. Harris MB, Shuster JJ, Pullen DJ, et al. Consolidation therapy with antimetabolite-based therapy in standard-risk acute lymphocytic leukemia of childhood: a Pediatric Oncology Group Study. J Clin Oncol. 1998;16:2840-2847.
101. Sallan SE, Hitchcock-Bryan S, Gelber R, et al. Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia. Cancer Res. 1983; 43:5601-5607.
102. Silverman LB, Declerck L, Gelber RD, et al. Results of Dana- Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981-1995). Leukemia. 2000;14:2247-2256.
103. Pession A, Valsecchi MG, Masera G, et al. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia. J Clin Oncol. 2005;23:7161-7167.
104. Rizzari C, Valsecchi MG, Arico M, et al. Effect of protracted high-dose L-asparaginase given as a second exposure in a Berlin- Frankfurt-Munster-based treatment: results of the randomized 9102 intermediate-risk childhood acute lymphoblastic leukemia study-a report from the Associazione Italiana Ematologia Oncologia Pediatrica. J Clin Oncol. 2001;19:1297-1303.